The Latest Breaking News from Obesity

Diabetes medications have started to gain attention for something other than their intended purpose: weight loss. Originally designed to manage blood sugar levels in patients with diabetes, these medications are now proving to be effective tools in the fight against obesity. As research grows, the narrative surrounding these drugs has…

Recent data reveals that the eurozone economy has narrowly skirted a recession, showing lukewarm yet positive growth. With the EU and euro area expected to grow steadily over the next two years, investing in quality stocks like Novo Nordisk (NVO), SAP SE (SAP), and Shell plc (SHEL) could be beneficial.…

Hims stock rallied almost 22% over two days on enthusiasm after the FDA said it will allow compounded versions of Lilly's obesity drug.

‘We cannot treat our way out of this’, says Stephen Powis, as doctors warn demand could overwhelm health service

Institute for Public Policy Research says firms that fail to offer options such as subsidised nutritious food should face censure

Health secretary Wes Streeting has said weight-loss jabs like Wegovy could be given to those who are unemployed

I've never really understood the concept of 'free votes' in parliament. The idea is that on issues of conscience, such as assisted dying or abortion time limits, MPs do not have to follow the party whip. Instead, they can vote as they wish, sometimes guided by their religious faith.

There was a moment a couple of years ago, as weight-loss injections first erupted into popular consciousness, when it looked as though they couldn’t possibly endure. All right-thinking people were, it seemed, reflexively horrified by the suddenly rampant use and abuse of Ozempic and its compatriots by Hollywood elites. Disturbing…

Everything you need to know about ‘skinny jabs’.

The new trial aims to gather evidence of the effects of the drug tirzepatide – sold by pharmaceutical company Lily under brand name Mounjaro

Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.